{"id":"pcv-chemotherapy","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":"50-70","effect":"Nausea and vomiting"},{"rate":"30-50","effect":"Peripheral neuropathy"},{"rate":"40-60","effect":"Fatigue"},{"rate":"40-60","effect":"Anemia"},{"rate":"20-40","effect":"Alopecia"},{"rate":null,"effect":"Secondary malignancy risk"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PCV is a multi-agent chemotherapy combination where procarbazine and lomustine act as alkylating agents that cross-link DNA and prevent replication, while vincristine is a vinca alkaloid that disrupts microtubule assembly during mitosis. This triple-agent approach targets rapidly dividing cancer cells through complementary mechanisms of cytotoxicity.","oneSentence":"PCV is a chemotherapy regimen combining procarbazine, lomustine (CCNU), and vincristine to disrupt cancer cell DNA and microtubule function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:01.043Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Recurrent or progressive glioblastoma"},{"name":"Anaplastic oligodendroglioma"},{"name":"Low-grade gliomas"}]},"trialDetails":[{"nctId":"NCT03313778","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2017-08-14","conditions":"Solid Tumors","enrollment":161},{"nctId":"NCT07448480","phase":"","title":"Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2026-02-01","conditions":"Recurrent Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma","enrollment":1000},{"nctId":"NCT05331521","phase":"PHASE3","title":"A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).","status":"RECRUITING","sponsor":"University Hospital Heidelberg","startDate":"2021-04-07","conditions":"Oligodendroglioma","enrollment":406},{"nctId":"NCT04702581","phase":"PHASE3","title":"A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2021-12-07","conditions":"Oligodendroglioma, Low-grade Oligodendroglioma, 1p19q Codeletion","enrollment":280},{"nctId":"NCT02444000","phase":"PHASE3","title":"gliomasPCV Only in 1p/19q Codeleted Anaplastic Gliomas","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-09-22","conditions":"Anaplastic Gliomas With 1p/19q Codeletion","enrollment":280},{"nctId":"NCT00887146","phase":"PHASE3","title":"Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2009-09","conditions":"Brain and Central Nervous System Tumors","enrollment":305},{"nctId":"NCT06518512","phase":"","title":"Automated Vision Assessment and Impairment Detection Through Gaze Analysis in Wet AMD Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tan Tock Seng Hospital","startDate":"2023-04-18","conditions":"Age-Related Macular Degeneration, Wet Age-related Macular Degeneration","enrollment":128},{"nctId":"NCT05296681","phase":"PHASE2","title":"Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery","status":"RECRUITING","sponsor":"Howard S. Hochster, MD","startDate":"2022-05-03","conditions":"Metastatic Colon Carcinoma, Stage IV Colon Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8","enrollment":42},{"nctId":"NCT07104266","phase":"PHASE2","title":"Triple Negative Breast Cancer and Celecoxib. Pilot Study","status":"RECRUITING","sponsor":"Université de Sherbrooke","startDate":"2025-08-04","conditions":"Triple-Negative Breast Cancer","enrollment":30},{"nctId":"NCT04541212","phase":"","title":"Identification and Evaluation of Patients at Risk of Developing Cardiotoxicity After Receiving Chemotherapy for Breast Cancer, Lymphoma or Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Montreal Heart Institute","startDate":"2021-12-02","conditions":"Breast Cancer, Lymphoma, Leukemia","enrollment":169},{"nctId":"NCT07007468","phase":"NA","title":"Prevention of Constipation in Cancer Patients","status":"RECRUITING","sponsor":"Marmara University","startDate":"2025-05-08","conditions":"Constipation Drug Induced","enrollment":146},{"nctId":"NCT05219110","phase":"NA","title":"Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2022-09-29","conditions":"Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome","enrollment":1040},{"nctId":"NCT05805800","phase":"PHASE3","title":"Olanzapine and 5-HT3 With or Without Dexamethasone to Prevent CINV","status":"COMPLETED","sponsor":"Xingchen Peng","startDate":"2023-04-15","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":275},{"nctId":"NCT06812221","phase":"PHASE1, PHASE2","title":"Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI","status":"COMPLETED","sponsor":"Biomind Labs Inc.","startDate":"2024-12-15","conditions":"Mild Cognitive Impairment, Anxiety State, Depression Anxiety Disorder","enrollment":20},{"nctId":"NCT00003375","phase":"PHASE2, PHASE3","title":"Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"1998-10","conditions":"Brain and Central Nervous System Tumors","enrollment":370},{"nctId":"NCT02068443","phase":"PHASE3","title":"Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-02","conditions":"Type 2 Diabetes Mellitus","enrollment":374},{"nctId":"NCT05438771","phase":"NA","title":"The Effects of Ankaferd Blood Stopper","status":"UNKNOWN","sponsor":"Uludag University","startDate":"2021-06-01","conditions":"Colon Cancer, Oral Mucositis, Nurse's Role","enrollment":66},{"nctId":"NCT04437017","phase":"PHASE3","title":"Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV","status":"COMPLETED","sponsor":"Fifth Affiliated Hospital, Sun Yat-Sen University","startDate":"2020-02-03","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":557},{"nctId":"NCT03161054","phase":"PHASE2","title":"Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2017-09-12","conditions":"Aggressive Non-Hodgkin Lymphoma","enrollment":21},{"nctId":"NCT02678975","phase":"PHASE2, PHASE3","title":"Disulfiram in Recurrent Glioblastoma","status":"COMPLETED","sponsor":"Sahlgrenska University Hospital","startDate":"2017-01","conditions":"Glioma, Glioblastoma","enrollment":88},{"nctId":"NCT01436669","phase":"NA","title":"Study of Home Full Blood Count (FBC) Telemonitoring Device for Chemotherapy Patient","status":"COMPLETED","sponsor":"Philips Healthcare","startDate":"2011-06","conditions":"Cancer","enrollment":20},{"nctId":"NCT04427644","phase":"","title":"Body Mass Index and Obesity Surgery Mortality Risk Score in Perioperative Complications of Laparoscopic Sleeve Gastrectomy","status":"COMPLETED","sponsor":"Kahramanmaras Sutcu Imam University","startDate":"2016-01-01","conditions":"Perioperative Complication, Laparascopic Sleeve Gastrectomy, BMD","enrollment":1617},{"nctId":"NCT01678352","phase":"EARLY_PHASE1","title":"Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas","status":"COMPLETED","sponsor":"Frank Lieberman","startDate":"2012-10","conditions":"High Risk WHO Grade II Glioma, Recurrent/Post-Chemotherapy WHO Grade II Glioma","enrollment":19},{"nctId":"NCT02297230","phase":"PHASE1, PHASE2","title":"Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2002-06","conditions":"Breast Cancer","enrollment":44},{"nctId":"NCT03662035","phase":"PHASE2","title":"Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Changzhou No.2 People's Hospital","startDate":"2018-09-15","conditions":"Advanced Pancreatic Cancer","enrollment":30},{"nctId":"NCT00258440","phase":"NA","title":"Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2003-05","conditions":"Anemia, Fatigue, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":7},{"nctId":"NCT02063854","phase":"PHASE2, PHASE3","title":"A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 Tablets","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-02","conditions":"Involutional Osteoporosis","enrollment":871},{"nctId":"NCT00002806","phase":"PHASE2","title":"Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"1996-07","conditions":"Brain and Central Nervous System Tumors","enrollment":43},{"nctId":"NCT02333513","phase":"NA","title":"A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation","status":"UNKNOWN","sponsor":"Hebei Yanda Hospital","startDate":"2015-02","conditions":"Recurrent High-grade Glioma","enrollment":100},{"nctId":"NCT00005796","phase":"PHASE1","title":"Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors","status":"COMPLETED","sponsor":"Indiana University","startDate":"2000-02","conditions":"Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ","enrollment":10},{"nctId":"NCT01786018","phase":"PHASE2","title":"Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas","status":"UNKNOWN","sponsor":"Azienda Ospedaliera San Giovanni Battista","startDate":"2013-02","conditions":"B-cell Lymphoma Refractory","enrollment":42},{"nctId":"NCT00431561","phase":"PHASE2","title":"Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma","status":"COMPLETED","sponsor":"Isarna Therapeutics GmbH","startDate":"2003-04","conditions":"Glioblastoma, Anaplastic Astrocytoma","enrollment":141},{"nctId":"NCT00003304","phase":"PHASE2","title":"Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1998-04","conditions":"Brain and Central Nervous System Tumors","enrollment":29},{"nctId":"NCT01504620","phase":"PHASE4","title":"Performance Evaluation of Blood Glucose Monitoring Systems","status":"COMPLETED","sponsor":"IKFE Institute for Clinical Research and Development","startDate":"2011-01","conditions":"Diabetes Mellitus","enrollment":106},{"nctId":"NCT01339988","phase":"PHASE4","title":"Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2011-06","conditions":"Acute Leukemias, Chronic Leukemias, Myelodysplastic Syndrome","enrollment":10},{"nctId":"NCT00331435","phase":"PHASE4","title":"PDT Study for Exudative AMD With PCV","status":"COMPLETED","sponsor":"Ophthalmic PDT Study Group","startDate":"2006-06","conditions":"Age Related Macular Degeneration","enrollment":113}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":141,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"PCV chemotherapy","genericName":"PCV chemotherapy","companyName":"Hospices Civils de Lyon","companyId":"hospices-civils-de-lyon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PCV is a chemotherapy regimen combining procarbazine, lomustine (CCNU), and vincristine to disrupt cancer cell DNA and microtubule function. Used for Recurrent or progressive glioblastoma, Anaplastic oligodendroglioma, Low-grade gliomas.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}